Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cybin Uses Psychedelic Mushroom Derivative To Tackle Depression With Improved Safety

Executive Summary

Emerging Company Profile: Cybin’s novel approach to psilocybin therapeutics aims for better safety, shorter duration and less variability through the process of deuteration.

You may also be interested in...



Cybin CEO: Big Pharma Can No Longer Sit On The Sidelines In Psychedelics

Podcast: Doug Drysdale, CEO of Cybin, tells Scrip about the controversial history of psychedelics and their potential role in addressing mental health disorders. The CEO also weighs in on consolidation in the psychedelic sector, which is currently dominated by biotech, and claims big pharma can no longer sit on the sidelines.

Cryptic Terran Licences Advanced CNS Assets From Sanofi

The US biotech has nabbed a couple of Sanofi’s Phase III CNS candidates, its third deal of the year aimed at transforming the neuropsychiatry market. 

IQVIA COVID-19 Vaccine Revenues To Soar But Pandemic Will Impact Overall Global Medicine Spending

While more money will be poured into COVID-19 vaccines, the pandemic's effects will be felt on overall growth of global medicine use following disruptions to patient engagement with healthcare, a new report from the IQVIA Institute for Human Data Science predicts.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel